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One of the main protagonists of 21st century biomedicine is not sick, at least not yet. She or he is 
pre-symptomatic, perhaps pre-disposed and certainly ‘at risk’. In Drugs for Life, Joseph Dumit 
accounts for the birth of a new statistical form of what he calls ‘mass health’ in America which is 
characterised by preventive treatment and knowledge of health through clinical trials. It is a style 
of medicine that is based on impermanent thresholds which are both divisive (as they corral ever 
more members of the general population into ‘at risk’ categories) and profoundly productive 
(generating a billion-dollar pharmaceutical industry intent on lowering thresholds and thereby 
increasing numbers of individuals who preventively take drugs for life). 
 Dumit’s point of departure is straightforward: how can it be that millions of people in 
America take statins to lower cholesterol or anti-hypertensives to lower blood pressure on a daily 
basis despite little or no experience of symptoms? To answer this question he proposes what we 
might call a Canguilhemian-ethnography, which is to say an ethnography that seeks to account for 
“a transition from an old to a new notion of health” (p.8), that is from individual health to mass 
health. What I mean by this is that the object of ethnography is neither a certain group of 
individuals (as found in classic medical anthropological studies) nor a particular kind of technology 
(as found in STS-inspired studies), even if both are very much present in the analysis. Instead, 
Dumit’s object of study is a particular notion of health or style of thought, or better yet, as he puts 
it the “naturalized logics” (p.18) of clinical trials and preventive treatment that configure mass 
health. The task has by no means been easy, as Dumit over the course of eight years has 
attempted to discern the logics of mass health among its producers, prescribers and users: at 
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pharma-conferences, through pharmaceutical advertisements and clinic trials data as well as 
through interviews with general practitioners and patients. This is assemblage (rather than multi-
sited) methodology, which in itself raises questions about the extent to which the coherence of 
the book’s analysis can be attributed to the field. 
 There are two key and inter-related findings in Drugs for Life. Firstly, Dumit identifies 
the processes through which new ‘at risk’ categories are produced as pharmaceutical companies 
calibrate large scale clinical trials to capture statistically significant treatment effects in the form of 
‘prevented’ clinical events (e.g. heart attacks or strokes). Embedded in the very construction of 
such trials is the idea that one must treat many to help a few, the so-called numbers needed to 
treat (NNT). Simply put, in order to prevent a few strokes, hundreds of pre-symptomatic 
individuals must take for example statins on a daily basis. This of course makes a lot of business 
sense so once statistical significance has been established, pharmaceutical companies go to work 
on members of the public to make them ‘risk aware’, providing simple means of online self-
diagnosis and encouraging them to talk to their doctors. In industry-jargon this is known as 
“conditioning the market for acceptance of new concepts” (p.64). 
 Secondly, Dumit charts what he calls ‘objective self-fashioning’, which he sees as 
those processes through which medical facts (such as a depression score or cholesterol threshold) 
come to be incorporated into the life of an individual who in turn comes to understand and act 
upon him or herself differently. The imperative to “know your numbers” coupled with adopted 
pharmaceutical lifestyles, Dumit argues, has led to new “modes of biomedical living” (p.182) which 
include expert patienthood (the ‘ideal’ patient who knows, monitors and acts upon his or her 
numbers), fearful living (the patient who is compelled by fear to adjust lifestyles) and playful living 
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(the “shut up and give me my Big Mac”-type use of pharmaceuticals). We have on a hitherto 
unprecedented scale, it seems, become pharmaceutical selves. 
 While Dumit’s is a critical study of mass health in the poststructuralist sense of 
wanting “to make our common sense about health seem a bit strange” (p. 21), he is also  
surprisingly (perhaps) critical, if not frightened by the prospects, of mass health. The tension 
between these two forms of critique surface especially in his conclusion which reads as a pre-
emptive set of frequently asked questions. As Dumit points out, the topic of his book is “deeply 
contradictory” (p.199); preventive medicine has certainly helped some (many?), but at what cost? 
Moreover, while Dumit’s argument of a shift from individual to mass health in America is 
compelling, and meticulously documented, we should not forget that millions of Americans and 
others continue to live, not just with risk, but with diagnosed diseases, with all the devastating 
consequences that can follow. 
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